Bo-Hyung Kim

Manipulation of organic cations and dimensional flexibility can improve the humidity stability of perovskites.

Many organic cations in halide perovskites have been studied for their application in perovskite solar cells (PSCs). Most organic cations in PSCs are based on the protic nitrogen cores, which are susceptible to deprotonation. Here, a new candidate of fully alkylated sulfonium cation (butyldimethylsulfonium; BDMS) is designed and successfully assembled into PSCs with the aim of increasing humidity stability. The BDMS-based perovskites retain the structural and optical features of pristine perovsk

WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT: The phosphodiesterase (PDE) type 5 inhibitor is a widely used agent that facilitates penile erection. Udenafil is newly developed as a PDE-5 inhibitor. WHAT THIS STUDY ADDS: This is the first study to determine the safety, tolerability and pharmacokinetics of udenafil in healthy subjects. Udenafil was safe and well tolerated in healthy Korean subjects. The AUC and C(max) of udenafil increased supraproportionally with increasing dose upon single administr

Bayesian therapeutic drug monitoring (TDM) software uses a reported pharmacokinetic (PK) model as prior information. Since its estimation is based on the Bayesian method, the estimation performance of TDM software can be improved using a PK model with characteristics similar to those of a patient. Therefore, we aimed to develop a classifier using machine learning (ML) to select a more suitable vancomycin PK model for TDM in a patient. In our study, nine vancomycin PK studies were selected, and a

Abstract Ojeok‐san is a frequently used herbal medication for the management of osteoarthritic pain. We evaluated the effect of Ojeok‐san on the pharmacokinetics of celecoxib at steady‐state in healthy individuals. An open‐label, fixed‐sequence, two‐period, two‐treatment cross‐over study was conducted. In period I, the individuals received celecoxib capsule 200 mg once daily for 4 days. In period II , only Ojeok‐san (14.47 g/pack, three times daily) was administered for 4 days, followed by co‐ad

BACKGROUND/AIM: Cancer stem cells (CSCs) and ABC transporters are associated with treatment resistance and outcomes of cancer patients. We aimed to investigate the prognostic implications of CSC markers and ABC transporters in colorectal cancer (CRC) patients. MATERIALS AND METHODS: We collected 331 CRC samples and evaluated 3 CSC markers (SOX2, LGR5, and ALDH1) and 3 ABC transporters (ABCC2, ABCC3, and ABCG2) by immunohistochemistry. The association between the expression of these protein and p

The selected covariates were generally consistent with previous studies. However, the mean volume of distribution was higher than the values reported in other population pharmacokinetic studies, which may have been due to the use of 2 sampling time points. The predictive performance was reasonably acceptable. Therefore, the present model may permit more accurate selection of doses to achieve target theophylline concentrations in premature infants.

Demethylsuberosin isolated from the roots of <i>Cudrania tricuspidata</i> demonstrated a potent proteasome activator by enhancing all three chymotrypsin-like, trypsin-like, and caspase-like proteasome activities in a 20S proteasome activity assay. It also attenuated the 1-methyl-4-phenylpyridinium-induced dysfunction of the chymotrypsin-like and caspase-like activities of proteasome in SH-SY5Y cells with EC₅₀ values of 0.76 µM and 0.82 µM, respectively. Additionally, demethylsuberosin

Pharmacokinetic/pharmacodynamic (PK/PD) models can be useful tools in new drug development and also optimal drug therapy in patients. This study was designed to develop a PK/PD model of sitagliptin based on the physiology of incretin. The PK/PD data included information derived from two different studies. Study 1 was conducted as a one-sequence, three-period, repeated-dose, dose escalation (sitagliptin 25, 50 and 100 mg q.d.) design in twelve healthy volunteers. Study 2 was a first-in-man study